Article Text

Download PDFPDF

579-A Targeting the NANOG-CRY1 axis sensitizes immunotherapy-refractory tumors and enhances efficacy of T cell-based immunotherapy by reinvigorating the anti-tumor immunity cycle

Statistics from Altmetric.com

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.